Pasithea Therapeutics
Pre-clinicalPasithea is developing new therapeutics for the treatment of neurological disorders, including solid tumors, Neurofibromatosis type 1 (NF1), Amyotrophic Lateral Sclerosis (ALS), and schizophrenia.
Founded
2020
Focus
AntibodiesBiologicsSmall Molecules
About
Pasithea is developing new therapeutics for the treatment of neurological disorders, including solid tumors, Neurofibromatosis type 1 (NF1), Amyotrophic Lateral Sclerosis (ALS), and schizophrenia.
Funding History
1SeedUndisclosedUndisclosedJun 15, 2021
Company Info
TypePrivate
Founded2020
LocationMiami Beach, United States
StagePre-clinical
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile